Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2006 1
2007 1
2009 1
2018 2
2021 2
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells.
Zhou G, Lieshout R, van Tienderen GS, de Ruiter V, van Royen ME, Boor PPC, Magré L, Desai J, Köten K, Kan YY, Ge Z, Campos Carrascosa L, Geuijen C, Sprengers D, van der Laan LJW, Verstegen MMA, Kwekkeboom J. Zhou G, et al. Among authors: geuijen c. Br J Cancer. 2022 Sep;127(4):649-660. doi: 10.1038/s41416-022-01839-x. Epub 2022 May 21. Br J Cancer. 2022. PMID: 35597867 Free PMC article.
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements.
Schram AM, Odintsov I, Espinosa-Cotton M, Khodos I, Sisso WJ, Mattar MS, Lui AJW, Vojnic M, Shameem SH, Chauhan T, Torrisi J, Ford J, O'Connor MN, Geuijen CAW, Schackmann RCJ, Lammerts van Bueren JJ, Wasserman E, de Stanchina E, O'Reilly EM, Ladanyi M, Drilon A, Somwar R. Schram AM, et al. Among authors: geuijen caw. Cancer Discov. 2022 May 2;12(5):1233-1247. doi: 10.1158/2159-8290.CD-21-1119. Cancer Discov. 2022. PMID: 35135829 Free PMC article.
A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade.
Geuijen C, Tacken P, Wang LC, Klooster R, van Loo PF, Zhou J, Mondal A, Liu YB, Kramer A, Condamine T, Volgina A, Hendriks LJA, van der Maaden H, Rovers E, Engels S, Fransen F, den Blanken-Smit R, Zondag-van der Zande V, Basmeleh A, Bartelink W, Kulkarni A, Marissen W, Huang CY, Hall L, Harvey S, Kim S, Martinez M, O'Brien S, Moon E, Albelda S, Kanellopoulou C, Stewart S, Nastri H, Bakker ABH, Scherle P, Logtenberg T, Hollis G, de Kruif J, Huber R, Mayes PA, Throsby M. Geuijen C, et al. Nat Commun. 2021 Jul 21;12(1):4445. doi: 10.1038/s41467-021-24767-5. Nat Commun. 2021. PMID: 34290245 Free PMC article.
Antibodies as drugs-a Keystone Symposia report.
Cable J, Saphire EO, Hayday AC, Wiltshire TD, Mousa JJ, Humphreys DP, Breij ECW, Bruhns P, Broketa M, Furuya G, Hauser BM, Mahévas M, Carfi A, Cantaert T, Kwong PD, Tripathi P, Davis JH, Brewis N, Keyt BA, Fennemann FL, Dussupt V, Sivasubramanian A, Kim PM, Rawi R, Richardson E, Leventhal D, Wolters RM, Geuijen CAW, Sleeman MA, Pengo N, Donnellan FR. Cable J, et al. Among authors: geuijen caw. Ann N Y Acad Sci. 2023 Jan;1519(1):153-166. doi: 10.1111/nyas.14915. Epub 2022 Nov 16. Ann N Y Acad Sci. 2023. PMID: 36382536 Free PMC article.
Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
de Vries Schultink AHM, Doornbos RP, Bakker ABH, Bol K, Throsby M, Geuijen C, Maussang D, Schellens JHM, Beijnen JH, Huitema ADR. de Vries Schultink AHM, et al. Among authors: geuijen c. Invest New Drugs. 2018 Dec;36(6):1006-1015. doi: 10.1007/s10637-018-0593-x. Epub 2018 May 5. Invest New Drugs. 2018. PMID: 29728897 Free PMC article.
12 results